CHICAGO--(BUSINESS WIRE)--RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development.
"We are very pleased to have Mark join us to lead our clinical development efforts"
Before joining RestorGenex, Dr. Weinberg served as Vice President, Global Clinical Science at Astellas Pharma Global Development. Prior to Astellas, he was Vice President, Medical Strategy and Medical Affairs at Lundbeck Inc. (formerly Ovation Pharmaceuticals). Previously, Dr. Weinberg held roles of increasing responsibility in clinical development at Takeda Global Research and Development and Abbott Laboratories. Dr. Weinberg earned his MD from Duke University Medical School and remained there to complete a residency in internal medicine. He also holds an MBA from the Kellogg Business School of Northwestern University and a BA in economics from Yale University.
"We are very pleased to have Mark join us to lead our clinical development efforts," said Stephen M. Simes, RestorGenex's chief executive officer. "We are planning to initiate several clinical trials in 2015 and Mark's experience and expertise will be critical to help maximize the success of our planning and implementation."
About RestorGenex Corporation
RestorGenex Corporation is a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health. The Company's prescription dermatology business primarily is based upon three compounds under development for the treatment of keloid scarring, androgen excess, e.g. acne, hirsutism (unwanted excess hair) and aging skin fragility/thinning. The Company's ophthalmology product will target age-related macular degeneration, based on inhibition of the PI3K/Akt/mTOR pathway. The Company's prescription women's health business is based upon a "soft" estrogen compound under development for vulvar and vaginal atrophy (VVA), a condition affecting peri- and post-menopausal women due to declining levels of estrogen. www.restorgenex.com
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about RestorGenex's intent to initiate clinical trials and other statements that are not historical in nature, particularly those that utilize terminology such as "will," "intends," "expects," "plans," "potential," "future," "believes," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among others, uncertainties regarding clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance and other risks and uncertainties described in RestorGenex´s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K/A, subsequent quarterly report on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex´s current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Tim Boris, 805-229-1829